OMDA

Omada Health, Inc.

Omada Health, Inc. (OMDA) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Value (C-). The rating has held at C+ for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C-
Factor Score 2.1 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
B+
Factor Score 3.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 36.7
EV / EBITDA 49.4
Rev Growth YoY 34.2%
Gross Margin 70.7%
Price Return 3M -39.7%
Price Return 12M -33.2%
Catalyst Signal 0.00
Market Cap $889.0M
TTM Revenue $333.0M
Price / Sales 2.7
ROE 5.7%

Historical Factor Score Progression

Held C+ for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C- (2.1) C+ (2.6) B+ (3.7) C (2.4) C+ (2.6) C+ (2.7)
2026-11-07 C- (2.0) C+ (2.8) B+ (3.6) C+ (2.7) C+ (2.7) C+ (2.8)
2026-10-31 D (1.3) B- (2.9) B+ (3.6) B- (3.1) C+ (2.7) C+ (2.7)
2026-10-24 D (1.4) B- (2.9) B+ (3.6) B- (2.9) C+ (2.6) C+ (2.7)
2026-10-17 D (1.5) B- (2.9) B+ (3.6) C+ (2.6) C+ (2.6) C+ (2.6)
Page 1 of 4